Citations

Clear

479 citation(s) found for "Tobias, JS".

Candida-Antigen Immune Reactivity in Subjects with Latent Tuberculosis Infection: A Shared Immunity?
Pennington, Kenneth R., Peikert, Tobias, Keulen, Virginia Van, Erskine, Courtney L. , Escalante, Patricio , Keulen, Virginia P. Van

Mayo Clinic

C106. BASIC AND TRANSLATIONAL DISCOVERIES IN TB AND MYCOBACTERIAL DISEASES | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6092-A6092

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6092 Get It

Comparison of PED and FRED flow diverters for posterior circulation aneurysms: a propensity score matched cohort study
Enríquez-Marulanda, Alejandro , Xiang, Sissi, Zhang, Hongqi , Waqas, Muhammad , Tutino, Vincent M. , Siddiqui, Adnan H. , Ogilvy, Christopher S. , Ulfert, Christian , Möhlenbruch, Markus , Renieri, Leonardo , Limbucci, Nicola , Burkhardt, Jan‐Karl , Kan, Peter , Rinaldo, Lorenzo , Brinjikji, Waleed , Spears, Julian , Broussalis, Erasmia , Koçer, Naci , Sonnberger, Michael , Engelhorn, Tobias , Ghuman, Mandeep S. , Salehani, Arsalaan , Harrigan, Mark R. , Radovanovic, Ivan , Chen, Karen , Aziz‐Sultan, Mohammad Ali , Ghorbani, Mohammad , Schirmer, Clemens M. , Goren, Oded , Dalal, Shamsher , Koch, Matthew J. , Stapleton, Christopher J. , Patel, Aman B. , Finkenzeller, Thomas , Holtmannspötter, Markus, Buhk, Jan Hendrik, Foreman, Paul M. , Cress, Marshall C. , Hirschl, Robert , Reith, W. , Janssen, Hendrik , Marotta, Thomas R. , Dmytriw, Adam A. , Waqas, Muhammad , Siddiqui, Adnan H , Levy, Elad I , Thomas, Ajith J , Renieri, Leonardo , Parra-Fariñas, Carmen , Rinaldo, Lorenzo , Brinjikji, Waleed , Müller-Thies-Broussalis, Erasmia , Killer-Oberpfalzer, Monika , Koch, Matthew J , Simgen, Andreas , Janssen, Hendrik , Marotta, Thomas R , Dmytriw, Adam A , Tutino, Vincent M , Schirmer, Clemens M , Ulfert, Christian , Limbucci, Nicola , Ogilvy, Christopher S , Griessenauer, Christoph J. , Hong, Tao , Taussky, Philipp , Grandhi, Ramesh , Levy, Elad I. , Lanzino, Giuseppe , Işlak, Civan , Yang, Victor X. D. , Mendes Pereira, Vitor , Krings, Timo , Matouk, Charles

Mayo Clinic

Journal of NeuroInterventional Surgery | July 1, 2020 | Volume: 13 | Issue: 2 | Pages: 153-158

10.1136/neurintsurg-2020-016055 | PMID 32611622 Get It

Abstract Background Flow diversion is a common endovascular treatment for cerebral aneurysms, but studies comparing different types of flow diverters are scarce. Objective To perform a propensity score matched cohort study comparing the Pipeline Embolization Device (PED) and Flow Redirection Intraluminal Device (FRED) for posterior circulation aneurysms. Methods Consecutive aneurysms of the posterior circulation treated at 25 neurovascular centers with either PED or FRED were collected. Propensity score matching was used to control for age, duration of follow-up imaging, adjunctive coiling, and aneurysm location, size, and morphology; previously ruptured aneurysms were excluded. The two devices were compared for the following outcomes: procedural complications, aneurysm occlusion, and functional outcome. Results A total of 375 aneurysms of the posterior circulation were treated in 369 patients. The PED was used in 285 (77.2%) and FRED in 84 (22.8%) procedures. Aneurysms treated with the PED were more commonly fusiform and larger than those treated with FRED. To account for these important differences, propensity score matching was performed resulting in 33 PED and FRED unruptured aneurysm pairs. No differences were found in occlusion status and neurologic thromboembolic or hemorrhagic complications between the two devices. The proportion of patients with favorable functional outcome was higher with FRED (100% vs 87.9%, p=0.04). Conclusion Comparative analysis of PED and FRED for the treatment of unruptured posterior circulation aneurysms did not identify significant differences in aneurysm occlusion or neurologic complications. Variations in functional outcomes warrant additional investigations.
Intraoperative Use of Betadine Irrigation is Associated With a 9-Fold Increased Likelihood of Penile Prosthesis Infection: Results From a Retrospective Case-Control Study
Manka, Madeleine, Yang, David Y. , Andrews, Jack R. , Hebert, Kevin , Köhler, Tobias , Trost, Landon , Manka, Madeleine G, Yang, David, Andrews, Jack, Chalmers, Brian , Hebert, Kevin J , Yang Md, David , Chalmers, Brian P.

Mayo Clinic

Sexual Medicine | June 26, 2020 | Volume: 8 | Issue: 3 | Pages: 422-427

10.1016/j.esxm.2020.05.010 | PMID 32601002 Get It

Abstract Introduction Infection remains a persistent complication of penile prosthesis (PP) surgery. Despite popularity of Mulcahy’s PP washout protocol, Betadine has known tissue toxicity. Aim We evaluated PP infection rate based on the type of intraoperative irrigation used, ½ strength Betadine vs vancomycin/gentamicin. Methods We reviewed a prospective database of men undergoing primary, revision, and salvage PPs. No other changes to operative or perioperative techniques occurred after the change in irrigation solution. Univariate and logistic regression analyses were used to evaluate differences in infection rate with use of Betadine vs vancomycin/gentamicin irrigation. Potential confounders were reviewed. Main Outcome Measure The primary outcome was rate of PP infection before and after change of intraoperative irrigation. Results From 2014 to 2018, 217 patients underwent PP placement at our institution by a single surgeon; of whom, 21 (9.7%) experienced an infection (primary = 10 [7.1%], revision = 11 [17.19%], salvage = 0 [0%]). Overall, 152 (70%) received irrigation with Betadine and 65 (30%) with Vancomycin/Gentamicin. Univariate analysis demonstrated significantly increased infection rates with Betadine irrigation (odds ratio [OR]: 4.64, P = .006) and with revision surgery (OR: 2.68, P = .02). Significance of increased infection rate with Betadine was maintained (OR: 9.3; P = .025) after controlling for age, body mass index, Charlson comorbidity index, smoking, diabetes, primary vs revision/salvage, prior penile surgery, use of ectopic reservoir, and adjunctive glanulopexy. Conclusions Changing from intraoperative Betadine to vancomycin/gentamicin solution dramatically reduced infection rates among men undergoing PP placement in both primary and revision cases. We hypothesize that differences in infection rate may relate to the relative toxicity or non-sterile nature of Betadine. Manka MG, Yang D, Andrews J, et al. Intraoperative Use of Betadine Irrigation is Associated With a 9-Fold Increased Likelihood of Penile Prosthesis Infection: Results From a Retrospective Case-Control Study. Sex Med 2020;8:422–427.
Noninvasive Pressure Flow Studies in the Evaluation of Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Review of 50,000 Patients
Kaplan, Steven A. , Köhler, Tobias , Kausik, Sankar J.

Mayo Clinic

Journal of Urology | June 22, 2020 | Volume: 204 | Issue: 6 | Pages: 1296-1304

10.1097/ju.0000000000001195 | PMID 32568608 Get It

Increased body mass index does not impact the imaging quality of focused assessment with sonography in trauma
Ifelayo, Oluwatomilona I., Oyemade, Kafayat A. , Tawfic, Sarah, Jeeji, Archana K., Ekstein, Samuel F. , Smoot, William A. , Voelkel, Jacob E., Laughlin, Michael J., Lohse, Christine M. , Kummer, Tobias , Bellamkonda, Venkatesh R. , Ifelayo, Oluwatomilona , Tawfic, Sarah S

Mayo Clinic

Journal of Clinical Ultrasound | June 19, 2020 | Volume: 48 | Issue: 8 | Pages: 452-456

10.1002/jcu.22884 | PMID 32557626 Get It

AbstractBackgroundMany clinicians believe that a patient's body mass index (BMI) affects the likelihood of obtaining high quality ultrasound images.ObjectivesTo assess the hypothesis that increased BMI is associated with worsening focused assessment with sonography in trauma (FAST) image quality.MethodsWe conducted a retrospective single‐center study of FAST examinations performed in a large academic emergency department (ED) with fellowship‐trained emergency ultrasonography faculty performing quality assurance review.ResultsMean (SD) BMI was 28.0 (6.6) among the 302 included studies. The overall quality rating tended to decrease as BMI increased but did not achieve statistical significance in a univariable setting (P = .06) or after adjustment for age and sex (P = .06). Operators perception of image adequacy was largely unaffected by BMI, with the exception of the pericardial view.ConclusionThis study did not identify a statistically significant difference in FAST quality with increased BMI. This result may help assuage clinician concerns about ultrasonography for patients in the ED.
Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence.
Tazelaar, Henry D. , Li, Yalun , Peikert, Tobias, Leventakos, Konstantinos , Chiou, Shih‐Hwa , Luo, Yung‐Hung , Liu, Han , Wampfler, Jason A. , Tazelaar, Henry D. , Liu, Dan , Chen, Yuh‐Min , Yang, Yanan , Yang, Ping

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e21631-e21631

10.1200/jco.2020.38.15_suppl.e21631 Get It

e21631 Background: The efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without T790M mutation remains unclear in real-world practice. We investigated whether osimertinib can provide survival benefit in EGFR-mutant patients without T790M mutation after 1st/2nd generation TKI treatment. Methods: Between January 1, 2009, and March 31, 2019, 417 patients had stage III-IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as≥2nd-line EGFR-TKI treatment were identified at Mayo Clinic. The time to treatment failure of osimertinib was analyzed by the Kaplan-Meier (KM) estimates. The risk of death post diagnosis was analyzed by Cox proportional hazard models. Results: Among 417 EGFR-mutant patients, higher risk of death was found in patients with age above 65 years, non-adenocarcinoma, no surgery treatment, no radiation treatment, non-exon 19 deletion/exon 21 L858R mutation, higher ECOG PS (2-4), PD-L1 expression of 50% or more, bone metastasis, live metastasis, and adrenal metastasis (all p < 0.05). Moreover, osimertinib as ≥2nd-line TKI treatment in patients with or without T790M revealed lower risk of death compared to 1st/2nd generation TKI treatment without subsequent osimertinib (HR = 0.33; 0.46, and p = 0.0002; 0.0232, respectively). However, among patients receiving osimertinib as ≥2nd-line TKI treatment, patients with T790M did not have superior survival than those without (p = 0.2803). Among 154 patients receiving osimertinib, a higher risk of treatment failure for osimertinib was found in male (HR = 1.72; p = 0.0327), patients with 1st-line TKI duration ≤12 months (HR = 2.16; p = 0.0019), BMI drop > 10% (HR = 1.85; p = 0.0207), PD-L1 levels of 50% or more (HR = 4.28; p = 0.0008), and 1st-line TKI with afatinib (HR = 2.19; p = 0.0136). Nonetheless, osimertinib as ≥2nd-line TKI in patients without 790M mutation did not have higher risk of treatment failure than those with T790M (p = 0.1236). Conclusions: This is the first study to demonstrate that osimertinib can provide similar survival benefit in previously EGFR-TKI treated NSCLC patients without T790M mutation as those with T790M in real-world practice. Additionally, EGFR-mutant patients with PD-L1 expression ≥50% had a higher risk of treatment failure for osimertinib and worse overall survival than those with PD-L1 expression < 50% and may potentially gain benefit from optimizing treatment strategies including immunotherapy.
A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG LU-006).
Yorke, Ellen , Voong, Khinh Ranh , Peikert, Tobias, Li, Zuofeng , Bradley, Jeffrey, Rimner, Andreas , Zauderer, Marjorie G. , Simone, Charles B. , Gill, Ritu R. , Tsao, Ming‐Sound , Rusch, Valerie W.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: TPS9079-TPS9079

10.1200/jco.2020.38.15_suppl.tps9079 Get It

TPS9079 Background: Pleurectomy/Decortication (P/D) with neoadjuvant or adjuvant chemotherapy has become a common lung-sparing surgical approach for MPM. Adjuvant hemithoracic IMPRINT was developed at Memorial Sloan Kettering Cancer Center and safe in a multi-institutional phase II study, with promising survival outcomes. The National Cancer Institute (NCI) sponsored this phase III randomized cooperative group trial to test the efficacy of this lung-sparing trimodality approach for resectable MPM. Methods: Patients with newly diagnosed MPM amenable to P/D are enrolled and undergo P/D followed by adjuvant platinum/pemetrexed (preferred) or neoadjuvant chemotherapy followed by P/D. Patients are stratified by histologic subtype, resection status (R0/1 vs. R2), and center patient volume (≤10 vs. > 10 P/Ds per year). Within 8 weeks after completion of the second modality patients are randomized 1:1 to undergo hemithoracic IMPRINT vs. no further therapy. All IMPRINT contours and treatment plans will be centrally reviewed. A contouring atlas and treatment planning constraints for target structures and organs at risk including acceptable and unacceptable variations and deviations were developed. Photon and proton therapy are permitted. The primary endpoint of the study is overall survival. Secondary endpoints include local failure-free, distant-metastases-free and progression-free survival, treatment-related toxicities (CTCAE v5.0) and change in quality-of-life (EORTC QLQ-C30 mean score changes at 9 months post randomization). The target accrual is 150 patients. This study was activated on January 29, 2020. Over 20 institutions have already committed to opening the study which is open to all National Clinical Trials Network (NCTN) sites. Treatment planning guidelines and helpful hints for photon and proton therapy will be presented. Conclusions: NRG LU-006 (clinicaltrials.gov: NCT04158141 ) is open to accrual. This is the first NRG Oncology randomized phase III trial on MPM and evaluates the use of IMPRINT following lung-sparing P/D and chemotherapy. This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), U24CA180803 (IROC) from the National Cancer Institute (NCI). Clinical trial information: NCT04158141.
Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.
Szlosarek, Peter W. , Moulec, Sylvestre Le , Planchard, David , Scherpereel, Arnaud , Jahan, Thierry, Koczywas, Marianna , Peikert, Tobias, Argon, Evren Kocabaş, Michaud, Neil R., Yang, Jay , Kansra, Vikram, Zauderer, Marjorie G. , Popat, Sanjay , Taylor, Paul D. , Forster, Martin D , Cameron, Robert Bruce , Fennell, Dean Anthony

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 9058-9058

10.1200/jco.2020.38.15_suppl.9058 Get It

9058 Background: Breast cancer gene 1 (BRCA1)-associated protein 1 (BAP1), a nuclear deubiquitinase, is commonly inactivated in malignant mesothelioma. Preclinical data showed that BAP1 inactivation sensitizes mesothelial cells to inhibition of enhancer of zeste-homolog 2 (EZH2), a methyltransferase implicated as an oncogenic driver in this tumor. This study evaluated the safety and efficacy of tazemetostat (TAZ), a potent and selective EZH2 inhibitor, in relapsed/refractory (R/R) malignant mesothelioma with BAP1-inactivation. Methods: EZH-203 (NCT02860286) was a 2-part, open-label, phase 2 study that assessed the pharmacokinetics (PK), safety, and efficacy of TAZ in pts with R/R malignant mesothelioma. In part 1, pts received TAZ 800 mg QD on day 1 (D1) and 800 mg BID, beginning day 2 of cycle 1 (C1). In part 2, pts received 800 mg of TAZ BID on D1 of C1. A two-stage Green-Dahlberg design was used for part 2. Primary endpoints were PK profiling of TAZ in all pts (part 1), and disease control rate (DCR) at week 12 in pts with BAP1-deficient R/R malignant mesothelioma (part 2). Secondary endpoints included safety, overall response rate (ORR), progression-free survival, overall survival, and duration of response (DOR). Results: The study enrolled 74 pts with R/R malignant mesothelioma, 70 pts (95%) were centrally confirmed to be BAP1-deficient. Median prior lines of therapy were 2 (range, 1-9). Observed clinical data in the presence of CYP3A4 inhibitors and inducers suggest a low DDI potential of TAZ. The 12 week DCR was 47% (n = 35). The ORR per RECIST version 1.1 was 3% [complete response: 0%; partial response (PR): 3% (n = 2)]. Of the 2 patients with PR, 1 had a DOR of 21 weeks and the other is ongoing (15.3 weeks at data cut off). 47 pts (64%) and 21 pts (28%) had stable disease (SD) and progressive disease, respectively. Overall, 91% pts discontinued, either due to disease progression (n = 65), death (n = 5), or treatment discontinuation (n = 1). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in ≤5% of patients, most commonly anemia (5%) and dyspnea (4%). No pts discontinued due to TEAEs. There were no treatment related deaths. Conclusions: Based on disease control rate and stable disease, TAZ showed antitumor activity in pts with BAP1-deficient R/R malignant mesothelioma. TAZ monotherapy was generally well-tolerated. The current data support further clinical evaluation of TAZ in these pts. Furthermore, this trial presents an optimal paradigm for drug development in molecularly-enriched cohorts in mesothelioma. Clinical trial information: NCT02860286.
A blood-based comprehensive and systems-level analysis of disease stages, immune regulation and symptoms in COVID-19 patients
Sadanandam, Anguraj , Bopp, Tobias , Dixit, Santosh, Emperumal, Chitra Priya , Rajalingam, Krishnaraj , Kannan, Nagarajan , Kannan, Nagarajan , Sadanandam, Anguraj , Knapp, David J. H. F. , Melcher, Alan

Mayo Clinic

No container title available | May 21, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-30473/v1 Get It

Abstract COVID-19 patients show significant clinical heterogeneity in presentation and outcomes that makes pandemic control and strategy difficult; optimising management requires a systems biology approach of understanding the disease. Here we sought to understand and infer complex system-wide changes in patients infected with coronaviruses (SARS-CoV and SARS-CoV-2; n=38 and 57 samples) at two different disease stages compared with healthy individuals (n=16) and patients with other infections (n=144). We applied inferential statistics/machine-learning approaches (the COVID-engine platform) to RNA profiles derived from peripheral blood mononuclear cells (PBMCs). Compared to healthy individuals, an integrated blood-based gene signatures distinguished acute-like (mimicking coronavirus-infected patients with prolonged hospitalisation) from recovering-like patients. These signatures also hierarchically represented systems-level parameters associated with PBMC including dysregulated cytokines, genes, pathways, networks of pathways/concepts, immune status, and cell types. Proof-of-principle confirmatory observations included PBMC-associated increases in ACE2, cytokine storm-associated IL6, enhanced innate immunity (macrophages and neutrophils), and lower adaptive T and B cell immunity in patients with acute-like disease compared to those with recovery-like disease. Patients in the recovery-like stage had significantly enhanced TNF, IFN-g, anti-viral, HLA-DQA1, and HLA-F gene expression and cytolytic activity, and reduced pro-viral gene expression compared to those in the acute-like stage in PBMC. Besides, PBMC-derived surrogate-based approach revealed overlapping genes associated with comorbidities (associated diabetes), and disease-like symptoms (associated with thromboembolism, pneumonia, lung disease and septicaemia). Overall, our study involving PBMC-based RNA profiling may further help understand complex and variable systems-wide responses displayed by coronavirus-infected patients.
Comparative Postoperative Outcomes of Rezūm Prostate Ablation in Patients with Large Versus Small Glands
Bole, Raevti , Gopalakrishna, Ajay , Kuang, Ruby , Alamiri, Jamal, Yang, David Y. , Ziegelmann, Matthew , Köhler, Tobias , Helo, Sevann , Ziegelmann, Matthew J, Yang Md, David

Mayo Clinic

Journal of Endourology | May 15, 2020 | Volume: 34 | Issue: 7 | Pages: 778-781

10.1089/end.2020.0177 | PMID 32408768 Get It